Cargando…

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized

Detalles Bibliográficos
Autores principales:	Gautier, A, Lowe, P, Skerjanec, A, McKernan, P, Luttringer, O, Fink, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952738/ http://dx.doi.org/10.1186/1546-0096-11-S1-A133

Ejemplares similares

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

P02-027 - Quality of life in CAPS treated by Canakinumab
por: Marsaud, C, et al.
Publicado: (2013)

PW02-026 - Low frequency variants of NLRP3 in CAPS patients
por: Lesche, M, et al.
Publicado: (2013)

P02-008 - Dramatic response to canakinumab in MKD
por: Makay, B, et al.
Publicado: (2013)

P02-029 - CAPS or SJIA
por: Alekseeva, E, et al.
Publicado: (2013)

PW02-031 - Genetic and clinical manifestations of CAPS
por: Bybee, AK, et al.
Publicado: (2013)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

PW01-026 – Validation of pediatric diagnostic criteria in FMF
por: Demirkaya, E, et al.
Publicado: (2013)

P02-033 - CAPS diagnosis and treatment in an Israeli family
por: Shinar, Y, et al.
Publicado: (2013)

PW02-033 - Cytokine profile in CSF in CAPS patients
por: Schuh, E, et al.
Publicado: (2013)

PW02-027 - CAPS and cost-effectiveness analysis project
por: Alberighi, O Della Casa, et al.
Publicado: (2013)

P01-026 – A case of FMF and hereditary coproporphyria
por: Ganesha, A, et al.
Publicado: (2013)

PW02-037 - The Eurofever cohort of 136 patients with CAPS
por: Levy, R, et al.
Publicado: (2013)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

P03-026 – Sweet’s syndrome: report of a new case
por: Mael-Ainin, M, et al.
Publicado: (2013)

PW03-026 - Caspase-1 variants involved in ER stress
por: Luksch, H, et al.
Publicado: (2013)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

PW02-034 - NLRP3 mosaicism detection in CAPS using NGS
por: Stoffels, M, et al.
Publicado: (2013)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

P02-032 - CAPS: a novel mutation and an unusual phenotype
por: Insalaco, A, et al.
Publicado: (2013)

PW02-025 - Programme necrosis by CAPS-associated NLRP3
por: Satoh, T, et al.
Publicado: (2013)

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

P02-020 - CAPS in Turkish children: treatment with ANTI IL1
por: Eroglu, FK Kara, et al.
Publicado: (2013)

PW02-039 - Long-term anakinra treatment in CAPS: a metaanalys
por: Leinonen, M, et al.
Publicado: (2013)

P02-021 - Atypical CAPS consequence of novel NLPR3 mutations
por: Gonzalez-Roca, E, et al.
Publicado: (2013)

P02-023 - NLRP3 mosaicism as a cause of late-onset CAPS
por: Zhou, Q, et al.
Publicado: (2013)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

PW02-028 - Association of novel NLRP3 mutations with CAPS phenotype in Turkish patients
por: Berdeli, A, et al.
Publicado: (2013)

PKPD modeling of acquired resistance to anti-cancer drug treatment
por: Eigenmann, Miro J., et al.
Publicado: (2017)

Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD
por: Morse, James Denzil, et al.
Publicado: (2023)

PhysiPKPD: A pharmacokinetics and pharmacodynamics module for PhysiCell
por: Bergman, Daniel, et al.
Publicado: (2022)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Opération piquet PO 2000-026
por: Royer, J P
Publicado: (2000)

“Daily life of CAPS patients treated with canakinumab (Ilaris(®)) : data from the French observational study - ENVOL Study”
por: Koné-Paut, I, et al.
Publicado: (2015)

Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies
por: Howard, Campbell, et al.
Publicado: (2014)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

PKPD Modeling of the Inoculum Effect of Acinetobacter baumannii on Polymyxin B in vivo
por: Chauzy, Alexia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ur64or9sdi91g5bg6a9o3p1tl